<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>BridgeBio</provider_name><provider_url>https://bridgebio.com</provider_url><title>Dosing of First Subject in Phase 1 Trial of BBP-418 | BridgeBio</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="HMcXucUX6x"&gt;&lt;a href="https://bridgebio.com/news/bridgebio-pharmas-ml-bio-solutions-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-bbp-418-for-limb-girdle-muscular-dystrophy-type-2i-lgmd2i/"&gt;BridgeBio Pharma&#x2019;s ML Bio Solutions Announces Dosing of First Subject in Phase 1 Clinical Trial of BBP-418 For Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://bridgebio.com/news/bridgebio-pharmas-ml-bio-solutions-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-bbp-418-for-limb-girdle-muscular-dystrophy-type-2i-lgmd2i/embed/#?secret=HMcXucUX6x" width="600" height="338" title="&#x201C;BridgeBio Pharma&#x2019;s ML Bio Solutions Announces Dosing of First Subject in Phase 1 Clinical Trial of BBP-418 For Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)&#x201D; &#x2014; BridgeBio" data-secret="HMcXucUX6x" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]&gt; */
&lt;/script&gt;
</html><description>ML Bio Solutions announced the first subject has been dosed in the Phase 1 clinical trial of BBP-418, a small molecule therapy for LGMD2i treatment.</description><thumbnail_url>https://bridgebio.com/wp-content/uploads/2019/02/BridgeBio_Share.png</thumbnail_url><thumbnail_width>1200</thumbnail_width><thumbnail_height>600</thumbnail_height></oembed>
